Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity of Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose, Influenza Vaccines, 2018-2019 Formulations

Trial Profile

Safety and Immunogenicity of Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose, Influenza Vaccines, 2018-2019 Formulations

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 10 Dec 2018 Status changed from recruiting to completed.
    • 26 Sep 2018 Planned number of patients changed from 240 to 120.
    • 26 Sep 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top